A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

InterMune

Status and phase: Completed; Phase 3

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: Interferon-gamma 1b

Study type: Interventional

Funder types: Industry

Identifiers

NCT00047645

GIPF-001

Details and patient eligibility

About

Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.

Enrollment: 330 patients

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Male or Female, 20-79 years old

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind